The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.

ABSTRACT: Anthracyclines, chemotherapeutic agents that have contributed to significant improvements in cancer survival, also carry risk of both acute and chronic cardiotoxicity. This has led to significantly elevated risks of cardiac morbidity and mortality among cancer survivors treated with these agents. Certain treatment related, demographic, and medical factors increase an individual's risk of anthracycline induced cardiotoxicity; however, significant variability among those affected suggests that there is an underlying genetic predisposition to anthracycline induced cardiotoxicity. The current narrative review seeks to summarize the literature to date that has identified genetic variants associated with anthracycline induced cardiotoxicity. These include variants found in genes that encode prot

SUBMITTER: Berkman AM 

PROVIDER: S-EPMC9902211 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature